Affinity BioReagents provides recombinant proteins and custom antibody-production services. The company had annual revenues of approximately $6 million in 2007, and will be integrated into Thermo Fisher’s analytical technologies segment.
Marijn Dekkers, president and CEO of Thermo Fisher, said: “This acquisition enhances our extensive antibody portfolio, which will drive growth as we combine these reagents with our current proteomics offerings to create end-to-end solutions for widely used protein-research applications.”